I’m a translational scientist at the intersection of computational biology and clinical resarch at the European Translational Oncology Prevention and Screening Institute (EUTOPS; Universität Innsbruck) and a honorary research fellow at the Institute for Women’s Health (University College London).
My work focuses on the association of
epigenetics (DNA methylation) with cancer risk and ageing. I’m passionate about harnessing epigenetics and other biomarkers for risk prediction, early detection, and monitoring of
personalized preventive strategies. Currently, I co-lead the clinical TirolGESUND study (ClinicalTrials.gov NCT05678426) alongside Prof. Martin Widschwendter (UIBK, UCL, Karolinska). This study aims to assess longitudinal changes in the epigenome and other biomarkers of ageing and disease in response to smoking cessation and intermittent fasting.
As part of the Biomarkers of Aging Consortium Roadmap Group, I actively promote standardisation for research into biomarkers of aging, and I have a special interest in employing more robust methods to advance molecular biomarkers into promising clinical tools for personalized disease prevention.
My work is driven by a commitment to improving healthcare through prevention and enhancing our understanding of age-related disease. I firmly believe that innovative research and collaborative efforts can pave the way for a more personalized and inclusive approach to health.
|Feb 15, 2024
|Validation of Biomarkers of Aging in Nature Medicine
|Feb 7, 2024
|New R package for STARD diagrams
|Jan 16, 2024
|Invited speaker at the Turn Around Aging Conference
|Dec 28, 2023
|I joined the Biomarkers of Aging Executive Committee
|Sep 28, 2023
|Investigating the interaction between genetic breast cancer risk and epigenome
- Validation of biomarkers of agingNature Medicine, 2024
- Biomarkers of aging for the identification and evaluation of longevity interventionsCell, 2023
- A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control SetsJournal of Clinical Oncology, 2022
- The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samplesNature Communications, 2022